Abstract
Apolipoprotein E4 (apoE4) is the major genetic risk factor for Alzheimers disease (AD) by an as yet to be defined mechanism. Since the structure or biophysical properties of a protein directly determines function, our approach to addressing mechanism is structure:function based. Domain interaction a structural property of apoE4 that distinguishes it from apoE3 is predicted to contribute to the association of apoE4 with AD. We developed a mouse model, the Arg-61 apoE model, which is specific for domain interaction. These mice display synaptic, functional, and cognitive deficits, demonstrating domain interaction is the causative factor. We present evidence that domain interaction results in stressed astrocytes that are dysfunctional and propose that dysfunctional astrocytes are an early player in apoE4-associated AD and that domain interaction is a potential therapeutic target.
Current Alzheimer Research
Title: Understanding the Basis for the Association of apoE4 with Alzheimers Disease: Opening the Door for Therapeutic Approaches
Volume: 6 Issue: 5
Author(s): Ning Zhong and Karl H. Weisgraber
Affiliation:
Abstract: Apolipoprotein E4 (apoE4) is the major genetic risk factor for Alzheimers disease (AD) by an as yet to be defined mechanism. Since the structure or biophysical properties of a protein directly determines function, our approach to addressing mechanism is structure:function based. Domain interaction a structural property of apoE4 that distinguishes it from apoE3 is predicted to contribute to the association of apoE4 with AD. We developed a mouse model, the Arg-61 apoE model, which is specific for domain interaction. These mice display synaptic, functional, and cognitive deficits, demonstrating domain interaction is the causative factor. We present evidence that domain interaction results in stressed astrocytes that are dysfunctional and propose that dysfunctional astrocytes are an early player in apoE4-associated AD and that domain interaction is a potential therapeutic target.
Export Options
About this article
Cite this article as:
Zhong Ning and Weisgraber H. Karl, Understanding the Basis for the Association of apoE4 with Alzheimers Disease: Opening the Door for Therapeutic Approaches, Current Alzheimer Research 2009; 6 (5) . https://dx.doi.org/10.2174/156720509789207921
DOI https://dx.doi.org/10.2174/156720509789207921 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
Current Alzheimer Research Author Index To Volume 5
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Current Drug Metabolism Current Rapid-Onset Antidepressants and Related Animal Models
Current Pharmaceutical Design The Obesity Hypoventilation Syndrome
Current Respiratory Medicine Reviews Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Long-Term Use of Short- and Long-Acting Nitrates in Stable Angina Pectoris
Current Clinical Pharmacology Editorial: Management of Diabetes in Unique Populations
Current Diabetes Reviews Monoterpenes as Perspective to Chronic Pain Management: A Systematic Review
Current Drug Targets Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Urinary Metabolite Profiles May be Predictive of Cognitive Performance under Conditions of Acute Sleep Deprivation
Current Metabolomics Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research Synthetic Strategies for Aspartic and Glutamic Acid-Proline Chimeras: A Review
Mini-Reviews in Organic Chemistry New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Fenofibrate Increases Heme Oxygenase 1 Expression and Astrocyte Proliferation While Limits Neuronal Injury During Intracerebral Hemorrhage
Current Neurovascular Research Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Pharmacologic Treatment with GABAB Receptor Agonist of Methamphetamine-Induced Cognitive Impairment in Mice
Current Neuropharmacology